Twelve reasons why it is worth to use atorvastatin/amlodipine fixed-dose combination – review of scientific reports Review article
Article Sidebar
Published:
Sep 30, 2014
Keywords:
arterial hypertension, dyslipidemia, amlodipine, atorvastatin, combination drug
Main Article Content
Abstract
Arterial hypertension and dyslipidaemia are major risk factors for cardiovascular mortality and morbidity. Patients taking antihypertensive drugs often also require concomitant use of lipidlowering drugs. Amlodipine/atorvastatin fixed-dose combination is new treatment option for patients with hypertension and coexistent dyslipidemia or coronary artery disease. The article presents 12 reasons why it is worth to use such a drug in clinical practice.
Article Details
How to Cite
Barylski , M. (2014). Twelve reasons why it is worth to use atorvastatin/amlodipine fixed-dose combination – review of scientific reports. Medycyna Faktow (J EBM), 7(3(24), 25-30. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2349
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. McKeage K., Siddiqui M.A.A.: Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am. J. Cardiovasc. Drugs 2008; 8: 51-67.
2. Wong N.D., Lopez V., Tang S. et al.: Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am. J. Cardiol. 2006; 98: 204-208.
3. MacDonald T.M., Morant S.V.: Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br. J. Clin. Pharmacol. 2008; 65: 775-786.
4. Masson R.P.: Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor. Drugs 2008; 68: 885-900.
5. Chapman R.H., Benner J.S., Petrilla A.A. et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005; 180: 137-143.
6. Bangalore S., Kamalakkannan G., Parkar S. et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007; 120: 713-719.
7. Patel B.V., Leslie R.S., Thiebaud P. et al.: Adherence with single pill amlodipine/atorvastatin vs two pill regimen. Vasc. Health Risk Manag. 2008; 4: 673-678.
8. Chapman R.H., Yeaw J., Roberts C.S.: Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees BMC Cardiovasc. Disord. 2010; 10: 29.
9. Delgado-Montero A., Zamorano J.L.: Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opin. Pharmacother. 2012; 13(18): 2673-2685.
10. Simons L.A., Ortiz M., Calcino G.: Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med. J. Aust. 2011; 195(3): 134-137.
11. Mason R.P., Kubant R., Heeba G. et al.: Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm. Res. 2008; 25: 1798-1806.
12. Charbonneau F., Anderson T.J., Title L. et al.: Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 2008; 197: 420-427.
13. Ge C.J., Lu SZ, Chen Y.D. et al.: Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 2008; 23: 91-95.
14. Fogari R., Preti P., Zoppi A. et al.: Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur. J. Clin. Pharmacol. 2006; 62: 817-822.
15. Koh K.K., Quon M.J., Han S.H. et al.: Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int. J. Cardiol. 2011; 146: 319-325.
16. Fogari R., Derosa G., Lazzari P. et al.: Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am. J. Hypertens. 2004; 17: 823-827.
17. Trion A., de Maat M., Jukema W. et al.: Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/ hCRP transgenic mice. J. Cardiovasc. Pharmacol. 2006; 47: 89-95.
18. van de Poll S.W., Delsing D.J., Jukema J.W. et al.: Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 2002; 164: 65-71.
19. Martin-Ventura J.L., Munoz-Garcia B., Blanco-Colio L.M et al.: Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int. Suppl. 2008; 111: S71-S74.
20. Cohn J.N., Wilson D.J., Neutel J. et al.: Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am. J. Hypertens. 2009; 22: 137-144.
21. Leibovitz E., Beniashvili M., Zimlichman R. et al.: Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am. J. Hypertens. 2003; 16: 715-718..
2. Wong N.D., Lopez V., Tang S. et al.: Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am. J. Cardiol. 2006; 98: 204-208.
3. MacDonald T.M., Morant S.V.: Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br. J. Clin. Pharmacol. 2008; 65: 775-786.
4. Masson R.P.: Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor. Drugs 2008; 68: 885-900.
5. Chapman R.H., Benner J.S., Petrilla A.A. et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005; 180: 137-143.
6. Bangalore S., Kamalakkannan G., Parkar S. et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007; 120: 713-719.
7. Patel B.V., Leslie R.S., Thiebaud P. et al.: Adherence with single pill amlodipine/atorvastatin vs two pill regimen. Vasc. Health Risk Manag. 2008; 4: 673-678.
8. Chapman R.H., Yeaw J., Roberts C.S.: Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees BMC Cardiovasc. Disord. 2010; 10: 29.
9. Delgado-Montero A., Zamorano J.L.: Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opin. Pharmacother. 2012; 13(18): 2673-2685.
10. Simons L.A., Ortiz M., Calcino G.: Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med. J. Aust. 2011; 195(3): 134-137.
11. Mason R.P., Kubant R., Heeba G. et al.: Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm. Res. 2008; 25: 1798-1806.
12. Charbonneau F., Anderson T.J., Title L. et al.: Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 2008; 197: 420-427.
13. Ge C.J., Lu SZ, Chen Y.D. et al.: Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 2008; 23: 91-95.
14. Fogari R., Preti P., Zoppi A. et al.: Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur. J. Clin. Pharmacol. 2006; 62: 817-822.
15. Koh K.K., Quon M.J., Han S.H. et al.: Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int. J. Cardiol. 2011; 146: 319-325.
16. Fogari R., Derosa G., Lazzari P. et al.: Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am. J. Hypertens. 2004; 17: 823-827.
17. Trion A., de Maat M., Jukema W. et al.: Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/ hCRP transgenic mice. J. Cardiovasc. Pharmacol. 2006; 47: 89-95.
18. van de Poll S.W., Delsing D.J., Jukema J.W. et al.: Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 2002; 164: 65-71.
19. Martin-Ventura J.L., Munoz-Garcia B., Blanco-Colio L.M et al.: Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int. Suppl. 2008; 111: S71-S74.
20. Cohn J.N., Wilson D.J., Neutel J. et al.: Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am. J. Hypertens. 2009; 22: 137-144.
21. Leibovitz E., Beniashvili M., Zimlichman R. et al.: Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am. J. Hypertens. 2003; 16: 715-718..